Copyright
©The Author(s) 2019.
World J Clin Cases. Nov 6, 2019; 7(21): 3384-3393
Published online Nov 6, 2019. doi: 10.12998/wjcc.v7.i21.3384
Published online Nov 6, 2019. doi: 10.12998/wjcc.v7.i21.3384
Table 2 Clinical outcomes of subtotal gastrectomy for remnant gastric cancer
| Ref. | Type of procedure | No. of patients | Operating time (min) | Blood loss (mL) | Retrieved lymph node | Hospital stay | Complica-tions | Follow-up (mo) | Recurrence/5-yr OS |
| Hosokawa et al[52], 2014 | SG | 13 | 174 ± 53.0 | 381 ± 372 | NA | 17.8 ± 8.7 | 23.10% | 99.2 | 0 |
| TG | 22 | 200 ± 59.8 | 597 ± 489 | NA | 18.6 ± 7.1 | 27.30% | 57.2 | 1 | |
| Irino et al[53], 2014 | SG | 24 | NA | NA | 18.5 (0–46) | NA | 29% | 36 | 94.10% |
| TG | 42 | NA | NA | 16.5 (3–86) | NA | 14% | 32 | 67.30% |
- Citation: Ma FH, Liu H, Ma S, Li Y, Tian YT. Current controversies in treating remnant gastric cancer: Are minimally invasive approaches feasible? World J Clin Cases 2019; 7(21): 3384-3393
- URL: https://www.wjgnet.com/2307-8960/full/v7/i21/3384.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v7.i21.3384